{"filings":[{"id":946596,"accession_number":"0001193125-26-263873","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-06-09T20:35:35+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Relay Therapeutics increases authorized common stock from 300M to 450M shares after stockholder approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares to 450M from 300M, a 50% increase.","Vote: 170,323,683 for, 909,020 against, 23,821 abstain; amendment effective June 9, 2026.","Directors elected: Douglas S. Ingram and Claire Mazumdar each received >120M votes for; 24.2M broker non-votes.","Non-binding say-on-pay approved: 143,849,919 for, 3,154,118 against, 51,787 abstain.","Ratification of Ernst & Young as independent auditor for FY2026: 171,030,133 for, 204,449 against, 21,942 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584116,"accession_number":"0001193125-26-234862","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-05-21T21:07:30+00:00","items":["1.01","9.01"],"status":"ready","headline":"Relay Therapeutics prices $316M public offering; underwriters exercise overallotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered underwriting agreement for 22,916,667 shares at $12.00/sh; full exercise of 3,437,500 overallotment option.","Net proceeds estimated at ~$296.8M after underwriting discounts and expenses; total shares offered 26,354,167.","Offering expected to close May 22, 2026, led by Jefferies LLC and TD Securities (USA) LLC.","Shares sold under existing shelf registration statement; significant dilution to existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":509238,"accession_number":"0001193125-26-229770","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-05-19T12:45:19+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics Announces Initial Phase 2 Data for Zovegalisib in Vascular Anomalies Showing 60% Response Rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.","89% of patients showed clinical improvement per investigator global impression at week 12; 79% per patient global impression.","Among 22 patients at 100mg and 300mg BID, no dose discontinuations; 9% had Grade 3+ TRAEs; no rash or stomatitis observed.","Expansion cohorts opened at 400mg QD and 300mg BID for adults/adolescents; pediatric dose-finding ongoing.","All 32 enrolled patients remained on treatment as of April 15, 2026 data cut-off; prior alpelisib/sirolimus use in 72%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95682,"accession_number":"0001193125-26-206398","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.","Median PFS 11.1 months in heavily pre-treated patients; similar efficacy across kinase and non-kinase mutations.","Phase 3 1L trial of zovegalisib+atirmociclib expected early 2027; Pfizer to supply atirmociclib.","Initiated Phase 1/2 trial of RLY-8161, an NRAS-selective inhibitor, in NRAS-mutant solid tumors.","Cash, cash equivalents and investments $642.1M; net loss $73.3M ($0.41 per share) for Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":3000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95681,"accession_number":"0001193125-26-179404","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.","Grade 3 hyperglycemia 0% despite 47% pre-diabetic; only 3% discontinued zovegalisib due to TRAEs.","Phase 3 trial of zovegalisib + atirmociclib + AI in 1L PIK3CA-mutated HR+/HER2- breast cancer expected to start early 2027.","Pfizer to supply atirmociclib and palbociclib for the trial; Relay retains full rights to zovegalisib.","Median follow-up 7.4 months; 77% of patients remain on study; median PFS not yet mature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108914,"accession_number":"0001193125-26-107312","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.","Confirmed ORR 43% overall (15/35) and 52% in second-line patients (11/21).","Safety consistent with prior 600mg fasted; only 4 of 60 patients discontinued due to TRAEs.","Pharmacokinetics of 400mg BID fed comparable to 600mg BID fasted; most patients above IC80.","FDA Breakthrough Therapy designation already granted; Phase 3 ReDiscover-2 trial ongoing since mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108913,"accession_number":"0001193125-26-102178","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Relay Therapeutics adopts exclusive federal forum for securities claims","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved second amended and restated bylaws effective March 6, 2026.","New exclusive forum provision requires securities law claims to be brought in federal district courts unless company consents otherwise.","Amendment covers claims under Securities Act of 1933 and Exchange Act of 1934.","No other material changes to bylaws were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108912,"accession_number":"0001193125-26-076617","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).","Cash, cash equivalents and investments $554.5M at Dec 31 2025, down from $781.3M; runway into 2029.","Revenue $7.0M in Q4 2025 (Elevar license) vs $0 in Q4 2024; full year revenue $15.4M.","Zovegalisib Phase 1/2 breast cancer data at ESMO TAT March 16 in 57 patients at Phase 3 dose.","Initial vascular anomalies data expected 1H 2026; pediatric cohort in ReInspire trial opened early."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":15355000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108911,"accession_number":"0001193125-26-034422","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay's zovegalisib granted FDA Breakthrough Therapy Designation for PIK3CA-mutant breast cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to zovegalisib + fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6i.","Supported by ReDiscover trial data: 600mg BID fasted (N=52) and 400mg BID fed (N=57, Phase 3 dose) with comparable exposures.","Phase 3 dose 400mg BID fed data to be presented first at ESMO Targeted Anticancer Congress on March 16, 2026.","BTD aims to accelerate development and review; provides Fast Track features and enhanced FDA guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125373,"accession_number":"0001193125-25-269536","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.","Cash, cash equivalents and investments $596.4M at Sep 30, 2025; expected to fund operations into 2029.","R&D expenses $68.3M, down from $76.6M YoY on streamlining and cost avoidance.","Board appointed Lonnel Coats and Habib Dable, former biotech CEOs, effective Nov 4, 2025.","Continued Phase 3 ReDiscover-2 trial and Phase 1/2 ReInspire trial in vascular malformations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":8355000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142096,"accession_number":"0000950170-25-105022","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.","Cash, equivalents and investments $656.8M, expected to fund operations into 2029.","RLY-2608 + fulvestrant Phase 1b data: 10.3-month median PFS, 39% ORR in PI3Kα-mutated HR+/HER2- mBC.","Initiated Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant vs capivasertib + fulvestrant.","R&D expenses decreased to $63.9M from $92.0M due to streamlining and license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":8355000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160068,"accession_number":"0001193125-25-139146","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.","Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.","Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.","She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.","Board determined Dr. Mazumdar is independent under Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160067,"accession_number":"0001193125-25-137162","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Relay Therapeutics stockholders elect directors and approve auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Alexis Borisy elected class II director with 80.7M votes for, 43.0M withheld.","Mark Murcko elected class II director with 79.5M votes for, 44.2M withheld.","Non-binding advisory vote on executive compensation approved: 69.7M for, 53.9M against.","Ratification of Ernst & Young as auditor for FY2025 passed with 142.2M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160066,"accession_number":"0001193125-25-134908","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Relay Therapeutics terminates Binney St lease early, signs Kendall Square lease; saves ~$16M in rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $2.5M modification fee and transferred FF&E to landlord to terminate Binney St lease early.","Paid $3.5M relocation fee for new 12,190 sq ft office at One Kendall Square, Cambridge.","Combined lease changes reduce total rent expense by ~$16M over remaining lease terms.","Continues to lease 41,474 sq ft at 60 Hampshire St (HQ) through June 2032.","Binney St lease originally set to expire April 2029; early termination tied to Kendall Square possession."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160065,"accession_number":"0000950170-25-063539","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q1 net loss $77M; cash runway into 2029, RLY-2608 Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $77.1M ($0.46/share) vs $81.4M ($0.62/share) in Q1 2024; revenue $7.7M from Elevar license completion.","Cash $710.3M; runway extended into 2029, funding ReDiscover-2 past topline and vascular malformations proof-of-concept.","Phase 3 ReDiscover-2 trial of RLY-2608+fulvestrant in breast cancer on track for mid-2025; ASCO abstract accepted.","Initiated Phase 1 RLY-2608 vascular malformations trial in Q1 2025.","Reduced workforce by ~70; research run rate cut ~80%; out-licensed RLY-4008 to Elevar with downstream economics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":7679000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178398,"accession_number":"0000950170-25-027733","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q4 net loss $0.45/sh; cash $781M; Phase 3 ReDiscover-2 trial mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $76.0M ($0.45/sh) in Q4 2024 vs $83.5M ($0.67/sh) in Q4 2023.","Cash, cash equivalents and investments of $781.3M at Dec 31, 2024, expected to fund operations into H2 2027.","Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in PI3Kα-mutated breast cancer to initiate mid-2025; 540 patients, PFS primary endpoint.","Phase 1b data showed 11.4-month median PFS and 39% ORR in 2L patients with PI3Kα-mutated HR+/HER2- advanced breast cancer.","Full year 2024 revenue $10.0M (down from $25.5M); net loss $337.7M ($2.36/sh)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":10007000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178397,"accession_number":"0000950170-25-004586","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relay Therapeutics to present at J.P. Morgan Healthcare Conference; no specific data disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing furnishes slides for 43rd Annual J.P. Morgan Healthcare Conference presentations on January 13, 2025.","Exhibit 99.1 is a company presentation; full content not provided in filing text.","No financial results, pipeline updates, or material events disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195055,"accession_number":"0000950170-24-135207","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports RLY-2608+fulvestrant median PFS 11.4 months in 2L breast cancer; plans pivotal study in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS 9.2 months overall, 11.4 months in 2L patients at RP2D (600mg BID) without PTEN/AKT co-mutations.","Confirmed ORR 39% overall, 67% in kinase-mutation patients; CBR 67%; median follow-up 9.5 months.","Low discontinuation rate (2 patients due to TRAEs); 94% median dose intensity; only 3% Grade 3 hyperglycemia.","Cash and investments ~$840M as of Q3 2024; funds 2L pivotal study planned for 2025.","Triplet combinations with ribociclib (ongoing) and atirmociclib (initiated) progressing; VMs study in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195054,"accession_number":"0000950170-24-122297","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics reports Q3 2024 net loss $88.1M; RLY-2608 shows 9.2-month median PFS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $88.1M ($0.63/share); revenue $0 vs $25.2M year ago (prior Genentech milestone).","Cash $839.6M at Sep 30, 2024; expected to fund operations into H2 2027.","RLY-2608 + fulvestrant interim data: 9.2-month median PFS, 33% ORR in heavily pre-treated PI3Kα-mutated breast cancer.","Plan to initiate Phase 3 pivotal trial of RLY-2608 + fulvestrant in 2L breast cancer in 2025.","Raised $230M in Sep 2024 follow-on; streamlined R&D with ~$50M annual savings, 15% workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":10007000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211337,"accession_number":"0001193125-24-217296","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics prices $200M public offering of common stock at $7.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 28.57M shares at $7.00/share; gross proceeds ~$200M.","Net proceeds estimated at ~$189.5M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to an additional 4.29M shares.","Offering expected to close on September 12, 2024; lead managers include Goldman Sachs, TD Cowen, Stifel, BofA Securities.","All shares sold by the company; proceeds will support clinical-stage precision medicine programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211336,"accession_number":"0000950170-24-104557","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay reports positive interim RLY-2608 data: 9.2mo PFS in PI3Kα-mutated breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS 9.2 months (all mutations) and 10.3 months (kinase mutations) at RP2D in heavily pre-treated patients without PTEN/AKT co-mutations.","ORR of 33% overall and 53% in kinase mutations; CBR 57%; tumor reductions in 73% of measurable patients.","Favorable tolerability: 95% median dose intensity, only 2 discontinuations due to TRAEs, 1 Grade 3 hyperglycemia, no Grade 4-5 TRAEs.","Lirafugratinib: FDA suggests file NDA in cholangiocarcinoma first, then tumor-agnostic sNDA; company seeks global partner.","Cash runway ~$688M into H2 2026; plan to initiate 2L pivotal study of RLY-2608 in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211335,"accession_number":"0000950170-24-091802","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q2 net loss $0.69/sh; cash $688M; new preclinical programs unveiled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $92.2M ($0.69/share) vs $98.5M ($0.81) in Q2 2023.","Cash, equivalents & investments $688.4M; expected to fund operations into H2 2026.","Announced 3 new preclinical programs: vascular malformations (PI3Kα), Fabry disease (non-inhibitory chaperone), NRAS-selective inhibitor.","Initiated Pfizer collaboration for RLY-2608 + fulvestrant + atirmociclib triplet; clinical start by end of 2024.","RLY-2608+fulvestrant doublet data update in Q4 2024 with ~100 patients safety database and ~60 at 600mg BID."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":10007000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211334,"accession_number":"0000950170-24-083928","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Genentech terminates migoprotafib collaboration; Relay loses future milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Genentech terminated without cause; effective 180 days after July 11, 2024.","Relay had received $121.8M total ($75M upfront + $45M milestones + R&D costs).","No further milestone or royalty payments due after termination date.","Relay regains full rights to migoprotafib (SHP2 inhibitor) and all associated data.","Termination removes expected future payments; drug development status uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229944,"accession_number":"0000950170-24-069674","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics announces Pfizer collaboration and three new pipeline programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical collaboration with Pfizer to evaluate RLY-2608 + atirmociclib + fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024.","New pre-clinical programs: vascular malformations, Fabry disease non-inhibitory chaperone, and NRAS-selective inhibitor, targeting over 200,000 U.S. patients.","RLY-2608 clinical development in vascular malformations expected Q1 2025; Fabry disease chaperone and NRAS inhibitor to enter clinic in H2 2025.","Cash runway guidance unchanged; $750 million expected to fund operations into second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229943,"accession_number":"0000950170-24-067952","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Relay Therapeutics annual meeting; executive compensation advisory vote passes with 60% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Sanjiv K. Patel (109.9M for) and Linda A. Hill (91.3M for) as class I directors.","Non-binding advisory vote on executive compensation passed: 66.7M for, 44.7M against (40% opposed).","Ratification of Ernst & Young as auditor for FY2024 approved with 119.4 million votes for.","Broker non-votes totaled 8.2M on director election and advisory compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229942,"accession_number":"0000950170-24-052110","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q1 net loss $81.4M; cash $749.6M, Genentech milestone boosts revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $81.4M ($0.62/share) vs $94.2M ($0.78/share) in Q1 2023; loss narrowed.","Revenue $10.0M vs $0.2M YoY, driven by $10M milestone from Genentech collaboration.","Cash and investments $749.6M, expected to fund operations into H2 2026.","R&D expenses $82.4M, relatively flat vs $82.8M year ago.","RLY-2608 doublet and triplet trials enrolling; lirafugratinib data and regulatory update expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":10007000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248399,"accession_number":"0000950170-24-018763","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q4 2023 net loss $83.5M; cash $750M funds into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $83.5M in Q4 2023 ($0.67 per share) vs $67.5M loss in Q4 2022.","Full year 2023 net loss $342.0M ($2.79 per share) vs $290.5M in 2022.","Cash, cash equivalents and investments $750.1M at Dec 31, 2023; expected to fund operations into H2 2026.","Completed enrollment in RLY-2608 600mg + fulvestrant dose expansion; initiated additional cohorts and triplet with ribociclib.","Deprioritized further clinical development of RLY-5836."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":25546000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248398,"accession_number":"0000950170-24-002682","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics raises $30M in PIPE with Nextech; proceeds for RLY-2608 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2.5M shares sold at $12.00 each (premium to Jan 5 close); gross proceeds ~$30M.","PIPE expected to close Jan 10, 2024; Nextech Crossover I SCP is the investor.","Proceeds to advance RLY-2608 toward registrational trial(s) and preclinical pipeline.","Company plans to disclose at least one new Dynamo platform program later in 2024.","Resale registration statement to be filed within 15 business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265894,"accession_number":"0000950170-23-058199","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q3 net loss $65.7M ($0.54), cash runway into H2 2026, advances lirafugratinib and RLY-2608","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.7M ($0.54/share) vs $84.2M loss ($0.76) in Q3 2022; revenue $25.2M from Genentech milestone.","Cash, equivalents, investments $810.6M; expects to fund operations into second half of 2026.","Lirafugratinib (RLY-4008): 35% ORR in FGFR2-fusion tumors, 40% ORR in FGFR2-altered HR+/HER2- breast cancer; pivotal CCA cohort fully enrolled.","Plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet in PI3Kα-mutant breast cancer by YE 2023; paused RLY-2139 (CDK2) development.","Paused near-term commercial readiness for CCA to focus on tumor-agnostic opportunity; next data/regulatory update in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":25547000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265893,"accession_number":"0000950170-23-053109","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports RLY-4008 data: 35% ORR in FGFR2 fusions; cash runway extended to 2H2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RLY-4008 achieved 35% ORR in FGFR2-fusion tumors (n=26) and 40% ORR in HR+/HER2- breast cancer (n=10); durable responses of ≥6 months in most responders.","In FGFR2-amplified tumors, 24% ORR (8/34) across multiple tumor types; early signals in FGFR2 mutations (3 PRs).","Safety profile consistent with prior data: no Grade 4/5 adverse events; off-target toxicities clinically insignificant.","Pipeline update: plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet by YE 2023; pause RLY-2139 (CDK2 inhibitor) development.","Cash runway extended by ~1 year, now sufficient into 2H2026; CCA commercial readiness paused to focus on tumor-agnostic opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283112,"accession_number":"0000950170-23-039822","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Relay Therapeutics Q2 net loss $98.5M; RLY-2608 dose expansion initiated with 86% CBR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $98.5M ($0.81/share) in Q2 2023, up from $76.8M loss ($0.71) in Q2 2022; R&D expenses rose to $88.2M.","Cash and investments $871.6M as of June 30, 2023; expected to fund operations into H2 2025.","Initiated RLY-2608 600mg BID + fulvestrant dose expansion; interim CBR 86% (6/7 evaluable pts) with 1 partial response.","No Grade 3+ hyperglycemia/diarrhea or AE-related discontinuations across 43 breast cancer patients; next data update in 2024.","Anticipated milestones: RLY-4008 pivotal cohort enrollment H2 2023, ERα degrader candidate nomination 2023, RLY-2139 start early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":345000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302497,"accession_number":"0000950170-23-025321","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Relay Therapeutics shareholders elect three directors, approve executive pay and auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Douglas S. Ingram, Sekar Kathiresan, and Jami Rubin elected as Class III directors with 103.3M, 104.6M, and 94.8M votes for, respectively.","Non-binding advisory vote on executive compensation approved: 97.8M for, 6.9M against, 70k abstained.","Ratification of Ernst & Young as independent auditor for FY2023: 112.2M for, 11.6k against, 40k abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302496,"accession_number":"0000950170-23-024290","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relay reports complete dose escalation data for RLY-4008; 73% ORR in FGFRi-naïve CCA at pivotal dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Among FGFRi-naïve FGFR2-fusion CCA patients at or above 70mg QD (n=11): 73% ORR, median DoR 11.2 months.","Patients at lower doses (n=14): 36% ORR; median DoR 5.6 months.","Safety consistent with prior data: no Grade 4/5 AEs; off-target hyperphosphatemia/diarrhea clinically insignificant.","Data cut-off Jan 30, 2023; presentation at ASCO on June 4, 2023.","Pivotal cohort enrollment completion and initial non-CCA expansion data expected in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302495,"accession_number":"0000950170-23-017857","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q1 net loss $94.2M; cash $937.8M; RLY-2608 shows no Grade 3 hyperglycemia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $94.2M ($0.78 per share) vs $62.0M ($0.57) in Q1 2022; R&D expense $82.8M up from $51.7M.","Cash, equivalents and investments $937.8M vs ~$1B at Dec 31 2022; expected to fund operations into 2025.","Initial RLY-2608 data at AACR: no Grade 3 hyperglycemia/rash/diarrhea at target exposures; one confirmed partial response in breast cancer patient after cut-off.","RLY-5836 first-in-human trial initiated in April 2023 for PIK3CA-mutant solid tumors; RLY-2139 candidate selected, clinical start early 2024.","Full RLY-4008 dose escalation data accepted at ASCO 2023; expansion cohorts for RLY-2608 planned H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":226000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302494,"accession_number":"0000950170-23-013199","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"RLY-2608 shows selective PI3Kα inhibition, no Grade 3 hyperglycemia, partial response in breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No Grade 3 hyperglycemia, rash, or diarrhea at target exposures; no dose-limiting toxicities or discontinuations.","Confirmed partial response (RECIST) in metastatic HR+/HER2- breast cancer patient with 12 prior lines of therapy.","Target exposure (~80%+ mutant PI3Kα inhibition) achieved at 400mg BID monotherapy and 600/800mg BID combination.","Nine of 16 breast cancer patients with measurable disease had radiographic tumor reductions; 11 remain on treatment.","Expansion cohorts expected in H2 2023; new first-in-human trial for second PI3Kα inhibitor RLY-5836 initiated April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322160,"accession_number":"0000950170-23-004106","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics reports Q4 2022 net loss of $67.5M; cash ~$1B funds into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.56 for Q4 2022, flat vs Q4 2021; full-year net loss $290.5M ($2.59/share).","Cash, cash equivalents and investments ~$1.0B as of Dec 31, 2022, up from $958.1M year-end 2021.","RLY-4008 interim data: 88% ORR at pivotal dose (70 mg) in FGFR2-fusion cholangiocarcinoma; registrational path set.","Breast cancer portfolio: RLY-2608 monotherapy and combination arms ongoing; initial data expected H1 2023.","Raised $300M gross proceeds in follow-on public offering; R&D expenses $246.4M for full year 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":1381000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322159,"accession_number":"0000950170-23-000426","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relay Therapeutics to present at 41st Annual J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will conduct meetings with participants at the 41st Annual J.P. Morgan Healthcare Conference during the week of January 9, 2023.","Slides for the presentation were furnished as Exhibit 99.1 to the Form 8-K.","The presentation is dated January 2023 and was filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340232,"accession_number":"0000950170-22-021868","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.","Cash and investments $1.1B as of Sep 30, 2022; sufficient to fund operations into 2025.","RLY-4008 interim data: 88% ORR at pivotal dose in FGFRi-naive FGFR2-fusion cholangiocarcinoma (n=17).","Raised $300M gross proceeds in follow-on public offering during Q3.","RLY-2608 (PI3Kα inhibitor) continues enrolling in single-agent and combination cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1128000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357495,"accession_number":"0000950170-22-018514","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics prices $300M public offering of 11.32M shares at $26.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 11,320,755 shares at $26.50/share; gross proceeds ~$300M.","Net proceeds expected ~$284.5M after underwriting discounts and expenses.","Underwriters granted 30-day option to buy up to 1,698,113 additional shares.","Offering expected to close on September 15, 2022; Goldman Sachs, J.P. Morgan, Cowen, BofA act as managers.","All shares sold by Relay Therapeutics; shelf registration effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357494,"accession_number":"0000950170-22-018311","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports 88% interim ORR for RLY-4008 in FGFR2-fusion CCA at pivotal dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["15 of 17 efficacy-evaluable patients at 70 mg QD achieved partial response (88% interim ORR); 14 confirmed, 1 unconfirmed.","13 of 15 responders remain on treatment; one patient resected with curative intent; two stable disease patients continue.","Across all doses/schedules, 24 of 38 FGFRi-naïve FGFR2-fusion CCA patients had partial response (63% interim ORR).","No Grade 4 or 5 adverse events; off-target toxicities (hyperphosphatemia, diarrhea) clinically insignificant.","Pivotal cohort enrollment expected to complete in H2 2023; initial non-CCA data and full dose escalation data expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357493,"accession_number":"0000950170-22-018205","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relay Therapeutics reports 88% ORR at RP2D for RLY-4008 in FGFR2 fusion CCA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At RP2D (70 mg QD), ORR 88% (15/17), confirmed ORR 82.4% (14/17), disease control rate 100%.","All-dose ORR 63.2% (24/38), confirmed ORR 57.9% (22/38), DCR 94.7%.","68% of patients remain on treatment; median follow-up 6 months (range <0.1-18.5).","No grade 4/5 treatment-related AEs; most common low-grade stomatitis (48%) and PPE (46%).","Abstract selected for oral presentation at ESMO Congress 2022 on Sept 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357492,"accession_number":"0000950170-22-014798","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q2 2022 net loss $76.8M; pipeline progress, new board member","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $76.8M ($0.71/share) in Q2 2022 vs $193.4M ($2.10) in Q2 2021; prior year included $134.9M ZebiAI acquisition costs.","Cash $838M as of June 30, 2022, down from $958M at Dec 31, 2021; expected to fund operations into at least 2025.","Appointed Sekar Kathiresan, CEO of Verve Therapeutics, to board of directors.","FDA alignment on single-arm trial for RLY-4008 in FGFR2-fusion CCA; interim data showed 62% confirmed partial response (8/13) at 70 mg QD.","Disclosed new breast cancer programs: selective CDK2 inhibitor, ERα degrader, and RLY-5836; RLY-2608 initial data expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":784000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357491,"accession_number":"0000950170-22-013150","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Relay Therapeutics appoints Sekar Kathiresan, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kathiresan appointed as class III director effective July 25, 2022, filling a newly created vacancy expanding board to eight members.","He is co-founder and CEO of Verve Therapeutics (VVTA) and serves on its board; previously director at MGH Center for Genomic Medicine and Broad Institute.","He will receive an initial option grant for 71,881 shares vesting over 36 months, plus standard non-employee director compensation.","Also appointed to the Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376091,"accession_number":"0000950170-22-012133","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Relay Therapeutics announces FDA alignment on RLY-4008 accelerated path; 62% response rate in CCA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA aligned on single-arm trial design for RLY-4008 at 70mg QD to potentially support accelerated approval in FGFRi-naïve FGFR2-fusion CCA.","Interim data: 8 of 13 (62%) FGFRi-naïve FGFR2-fusion CCA patients had confirmed partial responses; all 4 at 70mg QD responded.","Safety manageable: no Grade 4/5 AEs; off-target hyperphosphatemia and diarrhea clinically insignificant.","New breast cancer programs: selective CDK2 inhibitor (clinic Q4 2023/Q1 2024), ERα degrader (candidate 2023), pan-mutant PI3Kα RLY-5836 (clinic 2023).","Cash, cash equivalents and investments expected to fund current operating plan into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376090,"accession_number":"0000950170-22-010869","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Relay Therapeutics stockholders approve doubling authorized common stock to 300M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares from 150M to 300M (93,032,987 for, 758,293 against).","Directors elected: Alexis Borisy, Mark Murcko, Laura Shawver (class II, three-year term).","Non-binding advisory vote on executive compensation passed (83,645,401 for, 3,551,366 against).","Ratification of Ernst & Young as independent auditor for FY2022 approved (93,772,475 for, 15,739 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376089,"accession_number":"0000950170-22-007848","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q1 net loss $62M ($0.57/shr); cash $898M; RLY-2608 combo arm initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.0M ($0.57/shr) vs $42.2M ($0.47) in Q1 2021; R&D expenses rose to $51.7M.","Cash, equivalents and investments $898M (down from $958M at Dec 31, 2021); sufficient into 2025.","Initiated fulvestrant combination arm of RLY-2608 (pan-mutant PI3Kα inhibitor) dose escalation; initial data expected H1 2023.","RLY-4008 (FGFR2 inhibitor) received FDA orphan drug designation for cholangiocarcinoma; expansion cohorts enrolling.","Virtual analyst/investor event on June 27, 2022 to announce new target."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":419000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394434,"accession_number":"0000950170-22-001973","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics reports FY2021 net loss of $363.9M; cash $958M into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $67.5M vs net income $35.3M in Q4 2020; full-year net loss $363.9M ($3.82 loss per share).","Cash, cash equivalents and investments $958.1M at Dec 31 2021, expected to fund operations into at least 2025.","R&D expenses $172.7M for FY2021 (up from $99.9M in FY2020), driven by clinical trial and employee costs.","Announced interim data for RLY-4008 (FGFR2 inhibitor) showing tumor shrinkage in all six treatment-naïve FGFR2 fusion+ cholangiocarcinoma patients.","Dosed first patient in RLY-2608 (pan-mutant PI3Kα inhibitor) first-in-human trial; FDA granted orphan drug designation for RLY-4008 in cholangiocarcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":30290000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394433,"accession_number":"0000950170-22-000193","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Relay Therapeutics at JPM Conference; slides furnished without specific data in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company participated in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022.","Slides were made available but the full content is not excerpted in the 8-K filing.","No financial results, pipeline updates, or guidance changes are disclosed in the filing body.","The presentation is a routine investor event with no apparent material new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413043,"accession_number":"0001564590-21-059895","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Deep Nishar resigns from Relay Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dipchand (Deep) Nishar resigned as Class III director effective December 8, 2021.","Resignation was not due to any dispute or disagreement with the company, management, or board.","No replacement director has been announced in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413042,"accession_number":"0001564590-21-056202","cik":1812364,"company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Relay Therapeutics Q3 net loss $60.8M; cash + offering totals ~$1B, runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $60.8M ($0.66/share) vs $36.1M ($3.00/share) Q3 2020; R&D expenses nearly doubled to $45.0M.","Cash, equivalents, investments $616.5M at Sept 30, plus $402M net from follow-on offering, providing runway at least into 2025.","RLY-4008 interim data show selective FGFR2 inhibition; co to select RP2D and start expansion cohorts by end of 2021.","RLY-2608 preclinical data support it as first allosteric pan-mutant selective PI3Kα inhibitor; combination data at SABCS Dec 2021.","Follow-on public offering raised $402M gross proceeds, completed after quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":2462000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2779915332.63271,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-10T23:59:59+00:00|413042"}